Amendment Statement of Principles concerning acute myeloid leukaemia (No. 17 of 2020) (Cth)

Amendment Statement of Principles

concerning

ACUTE MYELOID LEUKAEMIA
(No. 17 of 2020)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

Dated      28 February 2020

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

Professor Nicholas Saunders AO
Chairperson

Contents

1Name........................................................................................................................................... 3

2Commencement........................................................................................................................ 3

3Authority..................................................................................................................................... 3

4Amendment............................................................................................................................... 3

1. Name

This is the Amendment Statement of Principles concerning acute myeloid leukaemia (No. 17 of 2020).

1. Commencement

This instrument commences on 23 March 2020.

1. Authority

This instrument is made under subsections 196B(2) and (8) of the Veterans' Entitlements Act 1986.

1. Amendment

The Statement of Principles concerning acute myeloid leukaemia (No. 71 of 2015) (Federal Register of Legislation No. F2015L00903) is amended in the following manner:

Section

Amendment

9(13a)

Insert the following factor in subsection 9(13a):

inhaling, ingesting or having cutaneous contact with dieldrin or aldrin for a cumulative period of at least 1 000 hours before the clinical onset of acute myeloid leukaemia, where the first exposure to dieldrin or aldrin occurred at least five years before the clinical onset of acute myeloid leukaemia;

9(13b)

Insert the following factor in subsection 9(13b):

inhaling, ingesting or having cutaneous contact with diazinon for a cumulative period of at least 1 000 hours before the clinical onset of acute myeloid leukaemia, where the first exposure to diazinon occurred at least five years before the clinical onset of acute myeloid leukaemia;